Correlation Between Eliem Therapeutics and PolyPid

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and PolyPid at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and PolyPid into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and PolyPid, you can compare the effects of market volatilities on Eliem Therapeutics and PolyPid and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of PolyPid. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and PolyPid.

Diversification Opportunities for Eliem Therapeutics and PolyPid

0.08
  Correlation Coefficient

Significant diversification

The 3 months correlation between Eliem and PolyPid is 0.08. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and PolyPid in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PolyPid and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with PolyPid. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PolyPid has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and PolyPid go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and PolyPid

Given the investment horizon of 90 days Eliem Therapeutics is expected to under-perform the PolyPid. In addition to that, Eliem Therapeutics is 1.35 times more volatile than PolyPid. It trades about -0.24 of its total potential returns per unit of risk. PolyPid is currently generating about 0.01 per unit of volatility. If you would invest  355.00  in PolyPid on September 1, 2024 and sell it today you would lose (9.00) from holding PolyPid or give up 2.54% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy98.41%
ValuesDaily Returns

Eliem Therapeutics  vs.  PolyPid

 Performance 
       Timeline  
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
PolyPid 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days PolyPid has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, PolyPid is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Eliem Therapeutics and PolyPid Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eliem Therapeutics and PolyPid

The main advantage of trading using opposite Eliem Therapeutics and PolyPid positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, PolyPid can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PolyPid will offset losses from the drop in PolyPid's long position.
The idea behind Eliem Therapeutics and PolyPid pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Complementary Tools

Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Fundamental Analysis
View fundamental data based on most recent published financial statements
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets